VolitionRX (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx Ltd. is a biotechnology company developing blood-based diagnostic tests designed to help detect and monitor cancer and other diseases. Its technology platform, Nu.Q, measures nucleosomes—small fragments of DNA and associated proteins released into the bloodstream during cell death—which may provide information about disease activity.

The company’s products include Nu.Q Vet, a suite of blood tests developed for veterinary oncology. The tests are intended to support cancer screening, diagnosis, and monitoring in dogs and other companion animals. VolitionRx is also developing human applications of its technology, including tests aimed at cancer detection, treatment monitoring, and the identification of neutrophil extracellular traps, or NETs, which are associated with inflammation and certain diseases.

VolitionRx was established in 2010 and operates internationally through subsidiaries and research activities in the United States and Europe. The company has focused on advancing and commercializing its Nu.Q platform through collaborations and distribution relationships in both veterinary and human healthcare markets. Cameron Reynolds has served as the company’s chief executive officer and president.

Key Stats

• Today's Range: $0.20 to $0.22
• 50-Day Range: $0.20 to $0.80
• 52-Week Range: $0.20 to $10.31
• Volume: 771,695 shs
• Average Volume: 3.37 million shs
• Market Capitalization: $2.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

VolitionRX Stock Analysis - MarketRank™

VolitionRX scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

VolitionRX has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

VolitionRX has a consensus price target of $28.00, representing about 13,686.3% upside from its current price of $0.20.

Amount of Analyst Coverage

VolitionRX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRX is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRX is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.42% of the float of VolitionRX has been sold short.

Short Interest Ratio / Days to Cover

VolitionRX has a short interest ratio ("days to cover") of 0.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VolitionRX has recently increased by 19.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRX does not currently pay a dividend.

Dividend Growth

VolitionRX does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for VNRX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

5 people have added VolitionRX to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VolitionRX insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of VolitionRX is held by insiders.

Percentage Held by Institutions

8.09% of the stock of VolitionRX is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:VNRX
• Previous Symbol: NYSEMKT:VNRX
• CIK: 93314
• Web: www.volition.com
• Phone: (646) 650-1351
• Fax: 65 32 8172 5651
• Employees: 75
• Year Founded: N/A

Price Target and Rating

• Average Price Target for VolitionRX: $28.00
• High Price Target: $60.00
• Low Price Target: $4.00
• Potential Upside/Downside: +13,686.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: -1,043.12%
• Pretax Margin: -1,046.83%
• Return on Equity: N/A
• Return on Assets: -303.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $1.73 million
• Price / Sales: 1.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.30) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 13,650,000
• Free Float: 12,707,000
• Market Cap: $2.77 million
• Optionable: Not Optionable
• Beta: 1.17